Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.4K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ARDS, Pneumonia, and Sepsis (APS) Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes.

Chest·2026
Same author

The Comparative Benefit of FFR-Guided Renal Stenting: 1 Year Results of the FAIR Trial.

JACC. Cardiovascular interventions·2026
Same author

Interdisciplinary perspectives on multi-risk anticipatory action.

iScience·2026
Same author

An international, multispecialty consensus document on the optimal management of patients with internal carotid artery occlusion.

Journal of vascular surgery·2026
Same author

A Comparison of Three Commonly Used Catheter Strategies in Diagnostic Transradial Coronary Angiography.

The American journal of cardiology·2026
Same author

Optimal treatment of preclinical cardiovascular disease: A narrative review with a focus on carotid artery stenosis.

Seminars in vascular surgery·2026

Related Experiment Video

Updated: Mar 13, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K

Renal Denervation for Resistant Hypertension.

John P Reilly1, Christopher J White2

  • 1Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute.

Progress in Cardiovascular Diseases
|October 30, 2016
PubMed
Summary

Renal denervation aims to treat hypertension (HTN) with less invasive methods. Current endovascular and non-invasive strategies show promise but haven't yet proven superior to medical therapy alone.

Keywords:
Anti-hypertensive agentsDenervationHypertensionSympathectomy

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

831
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.7K

Related Experiment Videos

Last Updated: Mar 13, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

831
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.7K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Nephrology

Background:

  • Hypertension (HTN) remains a significant global health concern.
  • Surgical splanchnicectomy is an effective but invasive treatment for HTN.
  • Minimally invasive endovascular approaches are being explored to replicate surgical outcomes.

Purpose of the Study:

  • To review the efficacy of endovascular and non-invasive renal denervation strategies for hypertension.
  • To analyze clinical trial data on renal denervation devices.
  • To identify shortcomings in current renal denervation research.

Main Methods:

  • Review of clinical trials investigating endovascular and non-invasive renal denervation.
  • Analysis of study designs and outcomes related to hypertension improvement.
  • Evaluation of the effectiveness and safety of various renal denervation systems.

Main Results:

  • Several renal denervation devices and procedures have been developed.
  • Clinical trials have explored improvements in hypertension management.
  • Current trials have not definitively shown superiority over medical therapy alone.

Conclusions:

  • Renal denervation offers a less invasive alternative to surgical HTN treatment.
  • Further rigorous randomized, double-blinded trials are needed.
  • Effective denervation systems are required to reduce hypertension risks.